中国疫苗研发牵动全球的心,美国人也终于意识到了:中国疫苗最安全,能救命!

继巴西州长对美国《财富》杂志称赞中国疫苗是全球最安全的疫苗之后,美媒再次发文称,“中国疫苗能救美国人的命”(A Chinese Vaccine Could Save American Lives)。

打开网易新闻 查看更多图片

彭博新闻社报道截图

美媒指责联邦政府不采购中国疫苗

明明是“最安全”、“最有希望

彭博新闻社在当地时间26日发布的一篇文章中指责美国政府不采购中国的疫苗。

报道称,在进一步临床试验和其他研究取得成果之前,美国并不清楚哪种新冠疫苗是最安全、最有效的,因此联邦政府提前购买了7种新冠疫苗。希望通过提前预定的方式,在必要时确保这些公司为加速生产做好准备。

Since it's impossible to know which vaccines for Covid-19 will be safest and most effective until the clinical trials are further along and other studies have been made, the federal government has made advance purchases of seven vaccines. By pre-purchasing a portfolio of vaccines, the US can ensure that when the time comes to ramp up production, the companies will be ready.

这些新冠疫苗的生产商大多是跨国公司,包括辉瑞、赛诺菲、阿斯利康以及强生等。在理想情况下,应该包括至少一个来自中国的疫苗。但目前为止,一个都没有

The current portfolio is multinational, including investments in Pfizer, Sanofi, AstraZeneca and Johnson & Johnson. Ideally, there should be at least one Chinese vaccine included, but there is not.

文章称,早前有些美国观察人士对中国疫苗研发的努力冷嘲热讽。如今,中国取得的成就非常显著。中国在疫苗研发方面的进展超过任何国家,目前已经有4个产品进入第三期试验。

Early in the process, some US observers went so far as to sneer at the Chinese vaccine efforts. But to date they have been impressive. China has made the fastest progress of any nation, and it has several vaccine contenders, with four products now in Stage 3 trials.

美国《财富》杂志援引巴西圣保罗州州长若昂·多利亚的评论称:在巴西进行临床研究的第一批结果表明,来自中国科兴生物制品有限公司的克尔来福新冠灭活疫苗(CoronaVac),是迄今为止在该国进行评估的最安全、最有希望的新冠疫苗

"The first results of the clinical study conducted in Brazil prove that among all the vaccines tested in the country, CoronaVac is the safest, the one with the best and most promising rates," So Paulo Gov. Joo Doria told reporters in Brazil on Monday.

戳图,看详细报道↓↓

医学杂志《柳叶刀》近期发表的一篇文章也持相同观点:中国疫苗的临床试验结果是“有希望的”、“足够安全的”

One recent paper in the medical journal The Lancet indicated a result of “promising” and also sufficiently safe.

《柳叶刀》文章截图

此外,报道还总结了中国研发、生产新冠疫苗具有的优势:

中国拥有广泛的信息集中能力,目前正在有效地以公开的方式加速开展第三期试验。

China, with its extensive information-gathering capabilities, is effectively conducting its Stage 3 trial in public, and at an accelerated pace.

中国疫苗都被设计用于快速生产和快速扩展,这对遏制疫情很有帮助。

Another advantage of the Chinese vaccines is that they are designed for quick production and rapid scalability.

中国疫苗这么好,为啥还不用?

美媒:怕被打脸

文章认为,美国政府早前多次就新冠疫情对中国进行抹黑、诋毁,现在来看,这样的宣传报道已经让美国进退两难。

总不能一边叫喊着“中国病毒”,一边又用中国生产的疫苗吧?如此一来,特朗普政府从未认真努力过与中国达成疫苗共享协议。

You can't call it "the Chinese virus" and then tell Americans they ought to take a Chinese vaccine. So the Trump administration has made no serious effort to make a vaccine-sharing deal with China.

如果最后美国还是要用中国的疫苗,那么对美国政府来说,这将是一次羞辱性的打脸。

但文章认为,考虑到新冠疫情给美国本土造成的巨大损害,为获得一种有效的疫苗而付出的代价是微不足道的。

It would probably qualify as a humbling propaganda defeat if America turned out to need a Chinese vaccine. But eating a little crow would be a small price to pay for a useful vaccine, given the immense damage wrought by Covid-19.

中国愿与全球分享疫苗成果

但美国就是不参与!

彭博新闻社在报道中表示,中国不仅疫苗质量好、生产速度快,更重要的是,中国愿与全球各国进行合作、共享。

早在2020年3月,中国就提出第一时间与全球共享病毒和病毒基因组序列,一直以来坚持通过国际合作来开展疫苗的研发工作。

10月8日,中国签署了疫苗共享多边协议,正式加入“新冠肺炎疫苗实施计划”(Covax)。

据悉,截至10月19日,已有184个国家和地区加入由世卫组织及其合作伙伴发起的“新冠肺炎疫苗实施计划”。

但美国并未加入。

China also just signed up for Covax, the vaccine-sharing multilateral arrangement. The US still has not joined.

在全球共同应对新冠病毒大流行的背景下,类似“退圈”“不合作”的场景,在美国已经多次上演。

当地时间9月11日,联合国大会通过一项决议,敦促加强国际合作与团结互助,以应对新冠疫情。

该决议获得169票赞成。而美国投出反对票,再次站在世界的对立面。

打开网易新闻 查看更多图片
绿色为赞成票,红色为反对票。

报道称,即便特朗普不是美国总统,没有中美贸易战,也不能保证美国就可以和中国达成一苗协议。

In all fairness, there is no guarantee that the US would have been able to strike a vaccine deal with China even if Trump were not president and there were no trade war.

对此,英国剑桥大学前高级研究员、中国问题专家马丁·雅克一针见血地指出,美国还在认为它是世界上唯一的主导者,但这已经不可能了。只有当美国认同必须与中国一道共同实施全球治理的时候,这种气氛和关系才会发生变化。

The Americans are insisting that they should enjoy sole primacy in the world. And this is no longer possible. This atmosphere and relationship will change at the moment when the United States comes to the view that it must share primacy in the world with China.

文章最后写道,中国以超乎大多数人想象的速度,成为全球生物医学领域的重要参与者。

现如今的中美贸易,不再仅仅是iPhone手机、大豆或是从沃尔玛买塑料玩具那么简单了,已经成为了一件生死攸关的大事

At a faster pace than most people would have thought possible, China has become a major player in the biomedical sciences. Trade with China isn't just about iPhones, soybeans and plastic toys at Walmart. These days, it is also a matter of life and death.

编辑:胡雨濛

实习生:张祺妍

中国日报(ID:chinadailywx)综合彭博新闻社等报道